NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. EAT

Go back to NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
(NASDAQ: ELDN) Delayed: 3.02 +0.09 (3.07%)
Previous Close $2.93    52 Week High $ 
Open $2.98    52 Week Low $ 
Day High $3.06    P/E N/A 
Day Low $2.93    EPS $ 
Volume 1,197,884